Intellia Therapeutics Will Appoint New Medical Chief
The Cambridge-based company announced that Dr. Jing L. Marantz will step into the role on October 26, 2026.
Updated on Oct. 13, 2026 in People
Intellia Therapeutics announced that Jing L. Marantz will become its new Chief Medical Officer starting October 26, 2026. She brings more than 25 years of biopharmaceutical industry experience to the leadership team.
Why it matters
The appointment comes as the Cambridge-based company prepares to commercialize its first in vivo gene editing product. This leadership change aligns with the firm's strategic focus on advancing Phase 3 clinical trials for transthyretin amyloidosis.
Jing L. Marantz brings over 25 years of experience to the role, where she will oversee translational, development, regulatory, and medical affairs functions. She holds a medical degree, a Ph.D., and an MBA from the University of California at Berkeley.
The players
Jing L. Marantz
A seasoned biopharmaceutical executive who holds both medical and doctoral degrees.
Intellia Therapeutics
A Cambridge-based biotechnology firm focused on developing in vivo gene editing therapies.
Scholar Rock
A biopharmaceutical company where Dr. Marantz previously held the position of Chief Medical Officer.
Arcturus Therapeutics
A biotechnology firm where Dr. Marantz serves as a member of the Board of Directors.
The details
Dr. Marantz joins the organization after serving as Chief Medical Officer for Scholar Rock and currently holds a seat on the Board of Directors for Arcturus Therapeutics. She is tasked with guiding the company through critical regulatory and clinical development milestones.
Timeline
The appointment was announced on October 13, 2026.
The role officially begins on October 26, 2026.
Market Landscape
This leadership appointment reflects the broader trend of biotech firms scaling executive teams to meet the rigorous demands of late-stage clinical commercialization. By securing a CMO with significant industry tenure, Intellia strengthens its position to compete in the complex gene-editing sector.
For investors and those following the biotechnology sector, this change signals the company's commitment to advancing its pipeline toward regulatory approval. The transition to a new medical lead is a critical benchmark as the company works to deliver its first commercial product to patients.
The takeaway
Adding veteran expertise to a leadership team is a common strategy for companies nearing pivotal trial completion. This transition helps ensure that the development and regulatory functions are prepared for the intensive demands of bringing a new gene therapy to the market.
Further reading
For more information on biotech leadership shifts, visit People.
